Acute Pancreatitis Following Brentuximab Vedotin Therapy for Refractory Hodgkin Lymphoma: A Case Report

Drugs in R and D - United Kingdom
doi 10.1007/s40268-014-0036-x
Full Text
Abstract

Available in full text

Categories
Pharmacology
Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Brentuximab Vedotin for Relapsed or Refractory Hodgkin Lymphoma: Experience in Turkey

Annals of Hematology
MedicineHematology
2014English

Brentuximab Vedotin for Relapsed or Refractory CD30+ Hodgkin Lymphoma: A Multicenter Analysis From Asia

OncoTargets and Therapy
OncologyPharmacology
2014English

Brentuximab Vedotin and Bendamustine as Salvage Therapy for Primary Refractory or Relapsed Hodgkin Lymphoma: A Multicentre Experience of the Polish Lymphoma Research Group

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Pulmonary Toxicity in Paediatric Patients With Relapsed or Refractory Hodgkin Lymphoma Receiving Brentuximab Vedotin

British Journal of Haematology
Hematology
2018English

Nivolumab for Relapsed/Refractory Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure – Polish Lymphoma Research Group Real-Life Experience

Acta Haematologica Polonica
OncologyHematology
2018English

Successful Rapid Desensitization to the Antibody–drug Conjugate Brentuximab Vedotin in a Patient With Refractory Hodgkin Lymphoma

Journal of Oncology Pharmacy Practice
MedicineOncologyPharmacology
2015English

Profile of Brentuximab Vedotin and Its Potential in the Treatment of Relapsed or Refractory Hodgkin Lymphoma

Blood and Lymphatic Cancer: Targets and Therapy
2012English

Brentuximab Vedotin Prior to Allogeneic Stem Cell Transplantation in Hodgkin Lymphoma: A Report From the EBMT Lymphoma Working Party

British Journal of Haematology
Hematology
2018English

Patient-Reported Outcomes of Brentuximab Vedotin in Hodgkin Lymphoma and Anaplastic Large-Cell Lymphoma

OncoTargets and Therapy
OncologyPharmacology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy